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To determine the prevalence of lung involvement and the spectrum of abnormalities revealed on HRCT in patients with AS, a
systematic literature review was conducted in the Medline database up to May 2009 and in the abstracts of rheumatology scientiﬁc
meetings (2006–2008). A hand search of references was also performed. Among the 264 selected articles, 10 articles (303 patients)
allowed a calculation of the prevalence of lung abnormalities on thoracic HRCT in AS. A total of 185 patients (61%) had an
abnormal thoracic HRCT: upper lobe ﬁbrosis in 21 (6.9%), emphysema in 55 (18.1%), bronchiectasis in 33 (10.8%), and ground
glass attenuation in 34 (11.2%). Non speciﬁc interstitial abnormalities were observed in 101 (33%) patients. The most common
observed abnormalities were pleural thickening (52%), parenchymal bands (45%) and interlobular septal thickening (30%). Only
the prevalence of upper lobe ﬁbrosis increased signiﬁcantly with disease duration (3 studies). Mild and non-speciﬁc interstitial
abnormalities on thoracic HRCT are common in patients with AS, even in patients with early disease and without respiratory
symptoms.
1.Introduction
Ankylosing spondylitis (AS) is a chronic rheumatic disorder
characterized by inﬂammation of the enthesis (especially
of the axial skeleton) and sometimes the joints, which
may lead to ankylosis [1]. AS is a multisystemic disease
and extraarticular features include uveitis, carditis, colitis,
and osteoporosis [2–4]. Lung involvement is now a well-
recognized extra-articular feature of AS. It was initially
described in 1941 [5]. However, it was considered as an
extra-articular manifestation of the disease only since 1965
[6]. The prevalence of pleuropulmonary involvement in AS
varies considerably (0–30%) in the medical literature. The
mostfrequentlyrecognizedpleuropulmonarymanifestations
are upper lobe ﬁbrosis, mycetoma formation, and pleural
thickening [7–12] .T h ea d v e n to fh i g hr e s o l u t i o nc o m -
puted tomography (HRCT) in the mid 1980s has allowed
physicians to examine the entire lung parenchyma and
pleura in many conditions with diﬀuse lung disease using a
noninvasive method [13].
The objective of this analysis was to determine the preva-
lence of lung involvement and the spectrum of abnormalities
revealed on HRCT in patients with AS according to the
disease duration and to describe its clinical characteristics by
as y s t e m a t i cl i t e r a t u r er e v i e w .
2.MaterialandMethods
To identify relevant studies, allowing calculation of the
prevalence of lung involvement in AS or to determine its
characteristics or both, a systematic analysis of literature was
performed in May 2009.
2.1. Literature Search Strategy. Publications were identiﬁed
in the PubMed Medline database up to May 2009 and in the
abstractsofEULAR(EuropeanLeagueAgainstRheumatism)2 Pulmonary Medicine
≪ankylosing spondylitis or spondylarthropathy [Mesh] and lung≫=261
articles
“ankylosing spondylitis and lung”: abstracts EULAR and ACR 2006, 2007, 
 2008 = 10 abstracts
Total: 271 abstracts
Publications excluded on the basis of 
the title and abstract: n = 213
- Inappropriate subject: n = 60 (no 
···etc.)
- Reviews:n = 46
- Articles twice:n = 3
Not in English or French: n = 55
Abstracts excluded: n = 21
- 2 original articles published
Publications excluded after
obtaining the full text: n = 41
No data on HRCT
Hand search of references: n = 3
Final analysis included 10 articles 
HRCT, functional studies, other 
diseases: sarcoidosis, rheumatoid 
arthritis, Behcet’s disease
- Letters and editorials:n = 4
- Cases reports:n = 45
48 publications selected
(303 patients)
- Inappropriate subject: n = 19
Figure 1: Flowchart summarizing the search process.
and the ACR (American College of Rheumatology) scientiﬁc
meetings of the years 2006, 2007, and 2008. Two searches
were carried out in the Medline database which used the
following key words: for the ﬁrst search “spondylarthritis”
or “ankylosing spondylitis” and “interstitial lung disease”
or “apical ﬁbrosis” (limits were English, French, humans);
for the second search “spondylarthritis” or “ankylosing
spondylitis” and “thoracic CT scan” (limits were English,
French, humans). Original articles were selected if they
reported the prevalence and/or the characteristics of lung
involvement on thoracic HRCT in AS. The analysis con-
cerned adults over 16 years old; studies concerning juvenile
arthritis were excluded. Lastly, a hand search of references
was also performed.
2.2. Data Collection. The articles were analysed by one
author (A. El Maghraoui) according to a predetermined
abstraction sheet. The following items were collected: num-
ber of AS patients (and criteria for the diagnosis), number
of patients reported as having lung involvement on HRCT,
sex, age at the moment of the study, disease duration, and
characteristics of lung involvement on HRCT.
2.3. Statistical Analysis. Statistics were descriptive. The
prevalence of lung involvement on HRCT was calculated
as the number of patients with AS presenting one or more
lesion on HRCT over the total number of patients with AS.
Standard deviations and means were calculated based on
available data.
3. Results
3.1. Article Selection. The Medline database and the congress
abstracts search yielded 261 articles. With the hand search
of references, a total of 10 articles were entered in the
analysis (Figure 1). Main reasons for exclusion were reviewsPulmonary Medicine 3
Table 1: Prevalence of thoracic HRCT abnormalities in patients with AS.
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Total: n (%)
N 26 21 20 28 55 17 38 20 52 26 303
Prevalence of abnormalities on
HRCT 18 15 17 18 31 15 27 10 21 13 185 (61)
Apical ﬁbrosis 2 3 5 1 5 2 1 2 21 (6.9)
Emphysema 4 2 9 5 6 13 2 5 9 55 (18.1)
B r o c h i e c t a s i s 623242 2483 3 ( 1 0 . 8 )
Ground glass attenuation 2 1 6 2 2 14 7 34 (11.2)
Non speciﬁc lung interstitial
abnormalities 11 6 9 10 26 10 19 10 101 (33.3)
Lymphadenopathy 3 6 9 (2.9)
Pleural thickening 1 6 9 13 3 13 4 4 53 (17.4)
M i c r o n o d u l e s 128771 343 3 ( 1 0 . 8 )
Pulmonary cysts 3 1 4 (1.3)
Bronchial wall thickening 4 6 2 12 24 (7.9)
Sub-pleural band 6 6 12 (3.9)
Parenchymal band 8 3 5 13 14 3 46 (15.1)
Irregular interfaces 3 4 7 (2.3)
Blebs 3 7 10 (3.3)
Intrelobular septal thickening 7 7 1 16 31 (10.2)
Linear septal thickening 6 9 6 21 (6.9)
Pleural tags 4 4 (1.3)
and case reports (42.7%), articles not related to AS or lung
involvement on HRCT (28.1%).
3.2. Prevalence. To calculate prevalence, a total of 10 articles
were assessed. All the studies were cross-sectional. The total
numberofpatientswithASwas303.ThediagnosisofASwas
based on modiﬁed New York criteria for all the patients [14].
Of 303 patients, 258 (85.1%) were male. Mean (SD) age was
40.7 (6.2) years. Mean disease duration was 11.7 (5.2) years.
Only 18 (5.9%) patients were reported to have pulmonary
symptoms, 73 (24%) were current smokers and 41 (13.5%)
ex-smokers.
A total of 185 patients (61%) was reported as having an
abnormal thoracic HRCT imaging. Among these patients,
upper lobe ﬁbrosis were observed in 21 (6.9%), emphysema
in 55 (18.1%), bronchiectasis in 33 (10.8%), and ground
glass attenuation in 34 (11.2). Nonspeciﬁc interstitial abnor-
malities were observed in 101 (33%) patients. The most
common observed abnormalities were pleural thickening
(52%), parenchymal band (45%), and intrelobular septal
thickening (30%) (Table 1).
Only 3 studies analyzed the prevalence of HRCT abnor-
malities according to disease duration. Among the 75 pa-
Table 2: Prevalence of thoracic HRCT abnormalities in patients
with AS according to disease duration.
Disease duration <5yrs 5–10yrs >10yrs P
Number of patients at risk 50 18 23
Ground glass attenuation 9 (18) 2 (11.1) 4 (17.3) 0.855
Upper lobe ﬁbrosis 3 (6) 2 (11.1) 5 (21.7) 0.049
Brochiectasis 9 (18) 1 (5.5) 5 (21.7) 0.881
Emphysema 11 (22) 3 (16.6) 8 (34.7) 0.309
tients at risk, the prevalence of upper lobe ﬁbrosis increased
with disease duration (Table 2).
4. Discussion
This systematic literature review reports the prevalence
and characteristics of chest HRCT abnormalities in AS.
In this systematic analysis, the prevalence of pulmonary
abnormalities in AS was high: 61% for a mean disease
duration of 11.7 (5.2) years. Upper lobe ﬁbrosis, with or
without cavitation, was a rare HRCT ﬁnding reported in
6.9%. Prevalence increased with disease duration in the few4 Pulmonary Medicine
studies where data were available. The main characteristic of
pulmonary abnormalities in AS was the high frequency of
mild nonspeciﬁc interstitial abnormalities. In this systematic
analysis, parenchymal bands and sparse thickening of the
interlobular septa, characterized as linear opacities, were the
most frequent ﬁndings considered as nonspeciﬁc interstitial
lung disease [15–26].
The interpretation of prevalence must take into account
disease duration. However, few studies analyzed the preva-
lence of lung abnormalities on HRCT according to disease
duration. Indeed, in this analysis the prevalence of upper
lobe ﬁbrosis in AS increased with the mean disease duration;
this prevalence reached 21% for a mean disease duration
>10 years. This was not the case for the other observed
abnormalities. However, it should be noted that these
analyses concerned mean disease duration, and not true
categories of disease duration, which is one of the limitations
of this work, which is unavoidable in systematic literature
reviews.
Smoking-induced lung disease is a complex group of
disorders, varying from the well-known entity of chronic
obstructive pulmonary disease to more recently described
interstitial lung diseases which may resemble to the reported
abnormalities described here [27]. Among the studied
patients in this systematic review, about 37% had a history
of smoking. However, no diﬀerences in prevalence of HRCT
lung abnormalities were noted between smokers and no
smokers.
The main limit of this systematic literature review is a
possible selection bias. None among the published studies
had a control group. Seven studies included consecutive
patients with AS without history of pulmonary symptoms
and excluded patients with history of tuberculosis, earlier
pneumonia, and exposure to dust or inhaled gases, while 2
studies included patients even when patients had pulmonary
symptoms and one study selected patients with no history of
smoking. With regard to the evaluation of CT abnormalities,
another limitation is that diﬀerent scanners were used
which may have hampered precise evaluation of subtle lung
changes. The analysis of images generated with diﬀerent
reconstruction algorithms may have aﬀected the detection of
mild ground-glass opacity.
The eﬀect of anti-TNF blockers on interstitial lung
ﬁbrosis and other abnormalities has never been evaluated.
However, this issue may become even more important as
these agents are now widely prescribed for AS [28, 29].
Moreover, many recent case reports described contrasting
eﬀects on pulmonary ﬁbrosis in patients with rheumatoid
arthritis (RA). Ostor et al. [30] reported fatal exacerbation of
RA-associated ﬁbrosing alveolitis in three patients receiving
inﬂiximab. On the other hand, Bargagli et al. [31]d e s c r i b e d
ab e n e ﬁ c i a le ﬀect of inﬂiximab in the treatment of RA
associated with interstitial lung disease.
The administration of anti-TNF agents is associated with
an increased risk of reactivation of latent tuberculosis even
though the measures recommended to screen and to prevent
this reactivation have been shown to be eﬀective [32]. Thus,
in clinical practice thoracic HRCT may be useful to identify
a suspicious abnormality in chest X-rays, especially when
anti-TNF therapy is planned. Clinicians must be aware of
the HRCT abnormalities observed in AS, which must not be
confounded with tuberculosis lesions.
In summary, this systematic review revealed a great
percentage of deﬁned as well as mild and nonspeciﬁc
interstitial abnormalities on thoracic HRCT undetectable on
plain radiography in patients with AS. These lesions are
common even in patients with early disease and without
respiratory symptoms. The signiﬁcance of such changes is
unknown and must await prospective longitudinal studies
to determine their natural history. Among the observed
lung abnormalities, only apical ﬁbrosis seemed to be more
prevalent with increasing disease duration.
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